Question 1

Has Jarushka Naidoo received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $1,629,467 in general payments to Jarushka Naidoo across 583 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Jarushka Naidoo did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Jarushka Naidoo come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
AstraZeneca	31	$1,061,430
Merck	7	$342,418
Incyte Corporation	483	$140,419
Astrazeneca UK Limited	12	$33,869
Daiichi Sankyo Inc.	22	$28,789
E.r. Squibb & Sons, L.L.C.	12	$16,967
F. Hoffmann-la Roche AG	3	$1,887
Takeda Pharmaceuticals U.S.A., Inc.	3	$1,533
Genentech, Inc.	3	$874
Gilead	1	$862
Genentech USA, Inc.	3	$232
Regeneron	2	$126
AbbVie	1	$60

Jarushka Naidoo

Payments from drug & device makers

Who reported the general payments

What the payments were tied to

How this compares

Other medical oncology in New York